CF Foundation Supports Work on Antifungal Therapy for Lung Transplants

CF Foundation Supports Work on Antifungal Therapy for Lung Transplants

313655

CF Foundation Supports Work on Antifungal Therapy for Lung Transplants

The Cystic Fibrosis Foundation announced a $3.5 million investment in Pulmocide to support the company in developing an inhaled medication, opelconazole, to prevent fungal infections — specifically Aspergillus — in lung transplant patients. This funding will go toward a planned, multicenter Phase 2 clinical trial of opelconazole to assess the therapy’s safety and tolerability. It will also evaluate transplant recipients’ ability to complete a course of the treatment in preventing fungal lung infections, and opelconazole’s…

You must be logged in to read/download the full post.